Skip to content

Nēsos receives FDA Breakthrough Device Designation for its disease-modifying digital therapeutic for Rheumatoid Arthritis Nēsos, the company developing disease-modifying digital therapeutics for inflammation-mediated disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its digital therapeutic for patients with rheumatoid arthritis (RA) who have had an inadequate response…

Read More

 The Lancet Rheumatology Publishes pilot clinical data showing promising efficacy and safety profile for e-mmunotherapy in Rheumatoid Arthritis patients. Fifty-three percent (53%) of patients receiving e-mmunotherapy, using the Nēsos earbud shaped neural interface, had meaningful reduction in disease activity after 3 months, while 37% of patients achieved low disease activity and 23% of patients achieved…

Read More